ReviewAnnals of translational medicine2020

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?

Stergios Boussios et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.